SAR443579

An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Near Add Your Location

Center of Excellence

  • Accepting patients

Center of Excellence

  • Accepting patients

Center of Excellence

  • Accepting patients

Center of Excellence

  • Accepting patients

Center of Excellence

  • Accepting patients
  • Accepting patients

Center of Excellence

Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
  • Accepting patients
  • Accepting patients
  • Accepting patients
506 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.